High tumor CXCL13 expression was associated with several factors that are generally associated with poor survival in breast cancer, such as low cancer histological grade of differentiation, high Ki-67 expression, and negative ER expression in the FinHer trial patient population. This evidence concerns the gene CXCL13 and cancer.